FDA's ODAC shrugs off ob­jec­tions to Mesoblast's GVHD drug for chil­dren, vot­ing 9-1 in fa­vor and im­prov­ing the odds of an ap­proval

The FDA’s On­co­log­ic Drugs Ad­vi­so­ry Com­mit­tee once again waved through an in­ves­ti­ga­tion­al drug, clear­ing the po­ten­tial fi­nal hur­dle be­fore the agency’s de­ci­sion.

Thurs­day’s win­ner was …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER